| Literature DB >> 31898845 |
Kejia Zhang1, Jenna M Lentini1, Christopher T Prevost1, Mais O Hashem2,3, Fowzan S Alkuraya2,3, Dragony Fu1.
Abstract
The human TRMT1 gene encodes an RNA methyltransferase enzyme responsible for catalyzing dimethylguanosine (m2,2G) formation in transfer RNAs (tRNAs). Frameshift mutations in TRMT1 have been shown to cause autosomal-recessive intellectual disability (ID) in the human population but additional TRMT1 variants remain to be characterized. Here, we describe a homozygous TRMT1 missense variant in a patient displaying developmental delay, ID, and epilepsy. The missense variant changes an arginine residue to a cysteine (R323C) within the methyltransferase domain and is expected to perturb protein folding. Patient cells expressing TRMT1-R323C exhibit a deficiency in m2,2G modifications within tRNAs, indicating that the mutation causes loss of function. Notably, the TRMT1 R323C mutant retains tRNA binding but is unable to rescue m2,2G formation in TRMT1-deficient human cells. Our results identify a pathogenic point mutation in TRMT1 that perturbs tRNA modification activity and demonstrate that m2,2G modifications are disrupted in the cells of patients with TRMT1-associated ID disorders.Entities:
Keywords: TRMT1; dimethylguanosine; intellectual disability; tRNA modification
Mesh:
Substances:
Year: 2020 PMID: 31898845 PMCID: PMC7981843 DOI: 10.1002/humu.23976
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878